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A cysteine-containing peptide motif, EWSPCSVTCG, is found highly conserved in the circumsporozoite
protein (CSP) and the thrombospondin-related anonymous protein (TRAP) of all the Plasmodium species
analyzed so far and has been shown to be crucially involved in the sporozoite invasion of hepatocytes. We have
recently shown that peptide sequences containing this motif, and also the antibodies raised against the motif,
inhibit the merozoite invasion of erythrocytes. However, during natural infection, and upon immunization with
recombinant CSP, this motif represents a cryptic epitope. Here we present the results of immunization studies
with two linear multiepitopic constructs, a 60-residue (P60) and a 32-residue (P32) peptide, containing the
conserved motif sequence. Both the peptides per se generated high levels of specific antibodies in BALB/c mice.
P32 was found to be genetically restricted to H-2d and H-2b haplotypes of mice, whereas P60 was found to be
immunogenic in five different strains of mice. The antibody response was predominantly targeted to the
otherwise cryptic, conserved motif sequence in P60. Anti-P60 antibodies specifically stained the asexual blood
stages of Plasmodium falciparum and Plasmodium yoelii in an immunofluorescence assay, recognized a 60- to
65-kDa parasite protein in an immunoblot assay, and blocked P. falciparum merozoite invasion of erythrocytes
in a dose-dependent manner. Immunization with P60 also induced significant levels of the cytokines interleu-
kin-2 (IL-2), IL-4, and gamma interferon in BALB/c mice. Moreover, >60% of mice immunized with P60
survived a heterologous challenge infection with a lethal strain of P. yoelii. These results indicate that
appropriate medium-sized synthetic peptides might prove useful in generating specific immune responses to an
otherwise cryptic but critical and putatively protective epitope in an antigen and could form part of a
multicomponent malaria vaccine.
Several antigens from different stages of the life cycle of the
malaria parasite Plasmodium falciparum have been character-
ized, and some of these, produced by recombinant DNA tech-
niques or by chemical synthesis, are being tested as vaccine
candidates (21, 22, 35). The circumsporozoite protein of P.
falciparum (PfCSP) is the best-characterized antigen of the
parasite because of its role in protective immunity against
preerythrocytic stages of malaria (29, 30). This protein con-
tains a stretch of highly conserved, immunodominant tetrapep-
tide repeats in the middle of its structure (13). However, clin-
ical trials with PfCSP peptides or recombinant CSP and its
fragments, aimed at developing specific antibody (Ab) re-
sponses to the repeats, have proved disappointing (2, 20). This
has led to the suggestion that there might be other antigenic
sites on the CSP; in fact, several B and T epitopes from the
nonrepeat region of CSP have already been characterized (17,
37). The CSPs of all Plasmodium species contain a nonrepeat
conserved portion termed region II. Further, a nonapeptide
motif (W-S-P-C-S-V-T-C-G) within region II has been found
highly conserved in all CSP sequences analyzed so far (32).
This conserved motif is also found in a variety of biologically
important proteins, such as thrombospondin, properdin, and
components of the complement pathways (19, 32). Interest-
ingly, this nonapeptide motif is also found in the throm-
bospondin-related anonymous protein (TRAP), first described
from erythrocytic stages of P. falciparum. Subsequently, TRAP
has also been shown on the surface of P. falciparum sporozo-
ites, and a homolog of TRAP, termed sporozoite surface pro-
tein 2 (SSP-2), was found on the surface of sporozoites of
Plasmodium yoelii (33, 34). Both CSP and TRAP (SSP-2) are
thought to have crucial roles in recognition and entry of sporo-
zoites into the liver cell, and in both, the conserved-motif
sequence acts as a specific sporozoite ligand for putative he-
patocyte receptors (7, 9, 10, 28). Recently a recombinant con-
struct, RTS, S, containing a truncated version of CSP, inclusive
of the region II sequence, attached to hepatitis core protein,
has been synthesized. The construct has been found to be
protective against sporozoite challenge in humans, raising
hopes of a single-antigen-based malaria vaccine (41).
The role of TRAP and, indeed, its expression and location at
the blood stages, is not yet known, although TRAP-specific
mRNA has been detected in infected erythrocytes (32). We
have recently shown that synthetic peptides representing the
conserved motif sequences and the antisera raised against
these peptides inhibited the merozoite invasion of erythrocytes
(38). Further, the anti-peptide Abs recognized a TRAP-like
molecule in the blood stage lysate of P. falciparum (38). A
better understanding of the structure of the region II peptide
sequences and immune responses against them may provide
the basis for their inclusion in a subunit malaria vaccine.
Vaccine constructs based on generating only Ab response
against well-characterized B epitopes from malaria antigens
have not met with the expected success, for several reasons (2,
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14, 20). There is now evidence to show that both Ab-mediated
and Ab-independent T-cell-mediated protection mechanisms
are operative at different stages of the parasite life cycle (4, 11,
45). Also, a successful malaria vaccine will be partly dependent
on natural boosting to maintain high levels of protective Abs
because of the impracticality of repeatedly administering a
vaccine, particularly in the third-world countries where such a
vaccine is most needed. To facilitate natural boosting, a vac-
cine would require T epitopes of parasite origin, and prefera-
bly the T and B epitopes should come from the same antigen
in the parasite. With this perspective, we have investigated the
immunogenicity of synthetic peptides containing B and T cell
determinants, based on CSP and TRAP sequences of P. falci-
parum, in mice (13, 17). We have found that a linear 60-
residue-long peptide (P60) containing the conserved region II
sequence (amino acids [aa] 331 to 390 of PfCSP) is highly
immunogenic in mice without the use of a carrier protein. We
describe here in detail the immunological characteristics of
P60. We also describe the synthesis and immunological prop-
erties of a chimeric peptide (P32) containing a T-cell epitope
overlapping with the conserved motif sequence and show evi-
dence that mice immunized with these two P. falciparum-based
peptides are partially protected against lethal challenge with
heterologous murine malaria blood stage parasites.
MATERIALS AND METHODS
Peptides. The amino acid sequences of the peptides P60 and P32 and their
constituent peptide fragments representing T1, T2, C1, P18, and PT18 are shown
in Fig. 1. The sequence of the 60-residue-long peptide P60 is from CSP of the
7G8 clone of P. falciparum, corresponding to residues 331 to 390 (13). The other
peptide, P32, is a chimeric peptide containing the T-helper sequence (T1; aa 331
to 347) from PfCSP as in P60, followed by the region II motif sequence (PT18;
aa 249 to 266) from TRAP of P. falciparum (PfTRAP) (13, 17). The differences
between region II of PfTRAP and that of PfCSP are shown in Fig. 1. The peptide
P32 is therefore highly homologous to the N-terminal half of P60. All the
peptides were synthesized on a 0.1-mmol scale with an automated peptide syn-
thesizer (model 430A; Applied Biosystems). The peptides were cleaved and
deprotected by treatment with either anhydrous hydrogen fluoride or triflu-
oromethanesulfonic acid, with thioanisole and ethanedithiol as scavengers.
Deprotected peptides were placed in reducing conditions, subjected to gel fil-
tration on Sephadex G-25 or G-10 columns, and purified by high-pressure liquid
chromatography on a C18 reverse-phase column with a gradient of acetonitrile in
0.1% trifluoroacetic acid as the eluant. Peptides P60 and P32 were characterized
by protein sequencing (model 477A sequencer; Applied Biosystems) and amino
acid analysis. All other peptides were checked by amino acid analysis.
Immunization of animals. Four- to 6-week-old mice of different inbred strains,
namely, BALB/c (H-2d), C3H/He (H-2k), C57BL/6 (H-2b), FVB (H-2b), DBA/2
(H-2d), and SJL (H-2S), were purchased from the Small Animal Facility of the
National Institute of Immunology, New Delhi, India. Two rabbits (New Zealand
White) were also procured from the same facility.
To find out whether P60, P32, and P18 were immunogenic on their own, three
groups of inbred mice (BALB/c; six per group) were immunized with 50 mg of the
given peptide dissolved in phosphate-buffered saline (PBS; pH 7.4) and emulsi-
fied in complete Freund’s adjuvant (CFA) via the intraperitoneal route. The
animals were boosted on days 28 and 35 with the same inoculum emulsified in
incomplete Freund’s adjuvant. The animals were bled on days 0 (preimmune),
14, 28, 35, 49, 64, 70, 100, and 120, and the sera were separated for immunoas-
says. Similarly, to analyze the pattern of genetic restriction of the immune
response to P60, mice belonging to different haplotypes were immunized as
described above and their sera were collected. All sera were heat inactivated and
stored at 220°C until used.
The rabbits were prebled and immunized subcutaneously at multiple sites with
250 mg of P60 dissolved in PBS (pH 7.4) per injection in an emulsion with CFA.
The first boost with the same amount of P60 in incomplete Freund’s adjuvant was
given 4 weeks later, followed by a second boost another 4 weeks later. Blood was
taken on days 0, 14, 28, 49, and 63. The sera were separated out in each case and
inactivated at 56°C for 30 min. The inactivated sera were diluted in 0.5% casein
in PBS (pH 7.4) prior to immunological analysis.
Antibody assays. (i) Affinity purification of immunoglobulins. Peptide-specific
Abs were purified from the rabbit anti-P60 sera by immunoaffinity chromatog-
raphy essentially as described in our earlier work (38). Briefly, gamma globulin
fraction from rabbit serum was obtained by ammonium sulfate precipitation
followed by ion-exchange chromatography on an Econo-Pac immunoglobulin G
(IgG) purification column (Bio-Rad Laboratories, Richmond, Calif.) according
to the manufacturer’s instructions. The purified IgG was then applied to the
FIG. 1. (A) Schematic representation of CSP and TRAP of P. falciparum indicating the location and sequence of region II (RII) in these proteins. Differences
between the two sequences of RII are underlined. (B) Schematic representation of P60 indicating the positions of T-helper (Th) T1 and T2, B RII, and CTL C1
epitopes. (C) Amino acid sequences of P60, P32, P18, and related peptides used in this study. The sequence of P60 is from the 7G8 clone of P. falciparum, whereas
P32 is a chimeric peptide containing a T-helper epitope; T1 is from CSP of P. falciparum (7G8 clone), and PT18 is from TRAP of P. falciparum.
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immunoadsorbent column prepared by the coupling of P60 to a cyanogen bro-
mide-activated Sepharose 4B column. The peptide-specific IgG Abs were eluted
with glycine-HCl buffer (0.1 M; pH 2.5), and the fractions were neutralized by the
addition of Tris base (2.0 M). The fractions were pooled and characterized as
described previously (38).
(ii) ELISA. Antibody levels in the sera from the mice immunized with the
peptides were assayed by enzyme-linked immunosorbent assay (ELISA), using
appropriate synthetic peptides as capture antigens. Briefly, the wells of flat-
bottom 96-well microtiter plates (Greiner, Nurtingen, Germany) were coated
with the relevant antigen. Uncoated reactive sites in the wells were blocked by
incubation with a 5% solution of a nonfat dried milk powder in PBS, pH 7.2, for
1 h. The plates were washed three times with washing buffer (0.15 M NaCl
solution containing 0.05% Tween 20). All serum samples were serially diluted in
PBS, pH 7.2, containing 0.5% milk powder and incubated in antigen-coated wells
for 90 min at room temperature in a humid chamber. The wells were washed
thoroughly with the washing buffer, and the plates were incubated with 50 ml of
optimally diluted horseradish peroxidase-conjugated goat anti-mouse IgG or
goat anti-human IgG (Sigma) for 90 min in the respective assays. The enzyme
reaction was developed with 100 ml of substrate solution (o-phenylenediamine
dihydrochloride [2 mg/ml] and H2O2 in citrate buffer, pH 5.0). The reaction was
stopped with 8 N H2SO4 (50 ml/well), and the optical density (OD) of the
reaction product was obtained with a microplate reader (Molecular Devices) at
490 nm. The last dilution of a test serum giving an OD value greater than twice
the OD value obtained with the respective preimmune serum diluted 1/100 was
taken as the endpoint titer. Sera obtained from the control mice receiving only
CFA were also screened for Abs to the relevant peptides.
(iii) Inhibition ELISA. Different concentrations of the relevant peptides were
preincubated with optimally diluted polyclonal anti-P60 Abs for 1 h at 4°C. The
plates, coated with P60 (1 mg/well) and blocked as described above, were then
incubated with 50 ml of the Ab-peptide solution for 30 min at room temperature
along with the polyclonal anti-P60 Abs diluted in 0.5% casein in PBS (pH 7.2)
without peptide. The plates were washed extensively with the washing buffer and
incubated with 50 ml of optimally diluted goat anti-mouse IgG for 90 min.
Following washings with washing buffer, the reaction was developed with 100 ml
of substrate solution (o-phenylenediamine dihydrochloride [2 mg/ml] and H2O2
in citrate buffer, pH 5.0). The reaction was stopped with 8 N H2SO4 (50 ml/well),
and the OD of the reaction product was obtained with a microplate reader
(Molecular Devices) at 490 nm. An unrelated linear 23-residue-long peptide,
VH-1, based on a plant protein (FLTTYAQAANTHLFLLKDAQIYG) was
used as a negative control in this assay.
(iv) Subtyping of IgG. The ELISA plate was coated with P60 and washed three
times with the washing buffer, followed by incubation of 50 ml of serially diluted
mouse anti-P60 serum samples in duplicate for 90 min. The plate was washed and
incubated with different goat anti-mouse IgG subtypes, namely, IgG, IgG1,
IgG2a, IgG2b, and IgG3 (diluted 1/1,000 in PBS [pH 7.4] containing 0.5% nonfat
dried milk) for 90 min. The plate was washed another three times with the
washing buffer and incubated with horseradish peroxidase-conjugated rabbit
anti-goat immunoglobulin (1/500) for 90 min, and the assay was completed as
described above.
IFA. Indirect immunofluorescence assays (IFAs) were performed with sera
obtained from BALB/c mice and rabbits immunized with P60 or P32. Briefly, the
wells of slides were coated with P. yoelii- or P. falciparum-infected erythrocytes.
The cells were fixed on slides by immersing them in cold acetone at 220°C for
2 h. The slides were incubated with different dilutions of sera in individual wells
for 1 h. After extensive washing with PBS, the slides were incubated with a 1:40
dilution of goat anti-mouse IgG conjugated to fluorescein isothiocyanate for 1 h
in the dark in a humid chamber. Following washings, the slides were observed
under a fluorescence microscope (Nikon) by visible and UV light alternately to
see specific binding of the antibody to the infected erythrocytes. Serum samples
obtained from rabbits immunized with adjuvant alone were also tested in this
assay and served as a negative control.
Western blot analysis. P. falciparum proteins were fractionated on sodium
dodecyl sulfate (SDS)–10% polyacrylamide gels under reducing conditions. Re-
combinant PfTRAP (a truncated version lacking the signal and transmembrane
sequences; residues 26 to 503) expressed in the pQE vector and recombinant
PfCSP (a kind gift from P. Sinnis) were also included in the gel. The fractionated
proteins were then electroblotted onto nitrocellulose paper. The parasite pro-
teins were probed with the polyclonal Ab raised against P60 in rabbit serum
(preadsorbed on human erythrocytes), followed by incubation with horseradish
peroxidase labelled anti-rabbit IgG. The reaction was developed with 3,39-dia-
minobenzidine as a substrate. In each case rabbit anti-parasite antibodies and
preimmune rabbit IgG or serum were used as a positive and negative control,
respectively. Monoclonal Ab (MAb) 2A10 (a kind gift from P. Sinnis) directed
against PfCSP and polyclonal serum raised against recombinant PfTRAP in
inbred female BALB/c mice served as positive controls for the respective recom-
binant proteins. The serum obtained from the adjuvant-immunized rabbit was
also screened for generation of the parasite-specific Abs.
Merozoite invasion inhibition and parasite growth inhibition assays. The
FID-3 isolate of P. falciparum was used for the merozoite invasion inhibition
assays. The parasite was cultured following methods described by Trager and
Jenson (42). For the merozoite invasion inhibition assay, cultures of the FID-3
isolate of P. falciparum were synchronized by two treatments with 5% sorbitol
(25) and incubated for about 30 h so that at the time of setting up the assay, more
than 95% of the parasites were late trophozoites. For the merozoite invasion
inhibition assay, the cultures were incubated for about 20 h with various con-
centrations of the immunoglobulin IgG, obtained from the rabbits immunized
with P60, as well as with the sera obtained from P32-immunized BALB/c mice.
Only the ring-stage-infected erythrocytes were counted as parasitized cells for
calculating percent parasitemia. In each case the sera obtained from rabbits
immunized with the synthetic peptide, P8 (LDNIKGNVGKMEDYIKKNNKC),
from merozoite surface protein 1 (MSP1) of P. falciparum, was used as the
negative control (39). Each serum or immunoglobulin concentration was tested
in triplicate. Percent invasion inhibition was calculated as follows: 100 2 (percent
parasitemia in test serum [immune immunoglobulin]/percent parasitemia in pre-
immune serum [or immunoglobulin] 3 100).
Cellular immune responses. (i) Lymphocyte proliferation assays. Two groups
of four mice each were primed with 50 mg of P60 or P32 in PBS emulsified with
equal volumes of CFA via tail base inoculations, while the group of control mice
received emulsified PBS alone. Twelve days later, the inguinal lymph nodes (LN)
were extracted and crushed to release the cells. The cells were washed twice with
RPMI 1640 medium (Sigma) and plated at 4 3 105/well in 96-well tissue culture
plates (Costar) in RPMI 1640 medium supplemented with 15 mM HEPES, 0.2%
sodium bicarbonate, 50 mM b-mercaptoethanol (Bio-Rad), 2 mM glutamine, 50
U of penicillin/ml, 50 mg of streptomycin/ml, and 10% fetal calf serum (Sigma).
Appropriate peptides were incubated with the seeded lymphocytes at different
concentrations. All cultures were set up in quadruplicate. The plates were incu-
bated at 37°C in 5% CO2 (Forma Scientific). Tritiated thymidine (0.5 mCi;
Amersham, Buckinghamshire, United Kingdom) was added to each well in the
last 15 h of the 5 days of culture. Cells were harvested, and the tritiated thymidine
incorporation was determined with a liquid scintillation counter (Betaplate;
Pharmacia, Uppsala, Sweden). Counts were derived from the averages of four
separate experiments and expressed as the stimulation index (SI) (SI 5 counts
per minute of stimulated culture/counts per minute of control culture). The
T-cell mitogen concanavalin A (Sigma) was used as a positive control.
(ii) Cytokine analysis. Supernatants were collected from in vitro lymphopro-
liferative cultures, growing in the presence or absence of the peptide, after 72 h.
Cytokine levels were estimated with the appropriate commercially available
murine ELISA kits (Endogen) according to the manufacturer’s instructions. The
cytokines interleukin-2 (IL-2), IL-4, and gamma interferon (IFN-g) were mea-
sured with 50 ml of supernatant diluted four times. The plates were read at a
wavelength of 450 nm. The concentration of each cytokine was calculated from
standard curves obtained with known concentrations of the positive control
provided with the respective kits.
Protection in mice. A group of 15 inbred mice (BALB/c) were immunized
intraperitoneally with 50 mg of P60 emulsified in CFA. Control mice received
only the adjuvant in PBS. All the mice received boosts on days 28 and 42. On day
49, the mice were bled and sera were collected. A week later, the immunized and
control mice were challenged with an inoculum of 104 Plasmodium yoelii nigerien-
sis (lethal strain)-infected erythrocytes. From the third day after the challenge,
thin blood smears obtained from each mouse were stained with Giemsa stain and
percent parasitemia was determined by microscopy. To assess the protective
potential of P32, a separate group of 10 BALB/c mice were immunized with the
peptide and challenged with P. yoelii parasites as described above. The protection
experiments were repeated twice to confirm the observations.
RESULTS
Immunoassays. We had found earlier that anti-region II
peptide Abs immunoreacted with a TRAP-like molecule in the
P. falciparum blood lysate (38). Since both P60 and P32 con-
tained the conserved region II sequences which are present in
both CSP and TRAP and which are also found conserved in
different plasmodium species (32), we wondered if anti-P60
Abs would also recognize antigens from the blood stages of P.
falciparum and P. yoelii. To investigate this, an indirect immu-
nofluorescence Ab test was carried out with sera from mice
immunized with P60 (Fig. 2). In an immunoblot the crude P.
falciparum lysate was probed with the rabbit anti-P60 serum
preadsorbed on human erythrocytes. Anti-peptide Abs recog-
nized a protein with a molecular mass in the range of 60 to 65
kDa (Fig. 3) in the lysate, as determined by prestained molec-
ular mass markers (SDS-7B; Sigma). The position of this pro-
tein band is somewhat lower than that we had observed in our
earlier work (38). In order to compare this protein band with
the other two well-known sporozoite stage proteins (CSP and
TRAP), which contain the conserved thrombospondin binding
motif, recombinant PfCSP and PfTRAP were also included in
this assay. Anti-peptide Abs recognized recombinant PfCSP as
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well as the truncated version of PfTRAP (37a) expressed in our
laboratory (Fig. 3). No further attempt was made to charac-
terize the 60- to 65-kDa protein at this stage. Anti-P. falcipa-
rum hyperimmune serum generated in a rabbit was used as a
positive control, whereas preimmune serum or purified immu-
noglobulins served as a negative control in this Western blot
analysis. Sera raised against the recombinant PfTRAP and
MAb 2A10 directed against the NANP repeats in PfCSP were
used to identify these proteins in this assay.
Merozoite invasion inhibition assay. The results of an ex-
periment to ascertain the effect of anti-peptide Abs on the
merozoite invasion of erythrocytes are summarized in Table 1.
We found that the addition of up to 10% normal rabbit serum
to the culture growing with 10% human serum did not affect
the rate of growth of the parasites. Incorporation of up to 10%
rabbit anti-P60 serum caused nearly 70% inhibition of mero-
zoite invasion. To further establish that the inhibition was due
to the presence of anti-peptide Abs, we tested affinity-purified
IgG fraction, obtained from rabbit anti-P60 serum, at different
concentrations in the above assay. We found (Table 1) that
while the rabbit immune IgG could inhibit merozoite invasion
in a dose-dependent manner (2 mg of purified IgG/ml caused
70% inhibition), the normal (preimmune) IgG showed a neg-
ligible effect on the invasion. Abs raised against a 21-residue
peptide, P8, representing a sequence from PfMSP1 (38),
showed no inhibition and served as a negative control in these
assays.
Protection in mice immunized with synthetic peptides. Since
the anti-P60 Abs showed reactivity with asexual blood stages of
both P. falciparum and P. yoelii in an IFA, we wondered if the
peptide immunization would also provide protection in mice
against murine malaria infection. To investigate this, a group
of 15 BALB/c mice immunized with P60 were challenged with
a lethal dose of asexual blood stages of P. yoelii nigeriensis. Ten
of the 15 immunized mice remained slide negative for the
parasite and survived the challenge. In two immunized mice,
parasitemia developed and reached a peak on days 6 and 12,
respectively, but decreased quite significantly thereafter. How-
ever, these mice died by day 14, perhaps due to other reasons,
such as anemia. In our analysis these mice were considered
unprotected. The three remaining mice showed a delayed on-
set of parasitemia compared to that in the control mice, but
they all died by day 9 after challenge. In a repeat experiment
essentially similar results were obtained. Control mice which
received only the adjuvant died within 10 days after the chal-
lenge inoculation (Fig. 4).
Mice (BALB/c) immunized with P32 and challenged as de-
scribed above also showed a similar pattern of protection; a
total of 7 of the 10 immunized mice survived the challenge. In
fact, six mice remained slide negative for the parasite, and in
the one in which parasitemia developed, the parasitemia de-
creased by day 14. In the three remaining mice there was a
delayed onset of parasitemia compared to that in the control
mice, but these mice died by day 14 (data not shown).
Humoral responses. Sera from mice immunized with P60,
P32, P18, and PT18 were tested by ELISA for the presence of
peptide-specific Abs. Anti-P60 Ab titers reached a peak at day
49, 7 days after the second boost (Fig. 5). The Ab levels re-
mained essentially the same for up to 150 days. Immunization
with P32 showed a similar pattern of Ab response (data not
shown). However, BALB/c mice immunized with carrier-free
P18 or PT18 did not produce detectable levels of peptide-
specific Abs. Control mice receiving adjuvant alone also did
not show any peptide-specific Abs.
In order to investigate the fine specificity of the humoral
response to P60 in BALB/c mice, ELISA was performed with
peptides representing different epitope sequences and peptide
FIG. 2. Immunofluorescence staining of the trophozoites P. falciparum with
anti-peptide serum. (A and B) Parasites showing bright fluorescent staining
under UV light. (C and D) The same fields under visible light, showing the
parasite-infected erythrocytes; some uninfected erythrocytes can also be seen in
these panels.
FIG. 3. Immunoblot showing the blood stage parasite protein recognized by
rabbit anti-P60 serum. A whole-cell lysate of the asexual blood stages of P.
falciparum and recombinant PfTRAP and PfCSP (without the signal sequence
and transmembrane domain) (lanes 3, 4, and 5, respectively) were fractionated
by SDS–10% polyacrylamide gel electrophoresis and probed with rabbit anti-P60
serum preadsorbed on human erythrocytes. Hyperimmune serum raised against
P. falciparum blood stages served as a positive control for the P. falciparum blood
stage lysate (lane 1), while MAb 2A10 served as a positive control for the
recombinant PfCSP (lane 6). Polyclonal sera raised in BALB/c mice served as
positive controls for the recombinant TRAP in this assay (lane 7) and the
preimmune serum served as a negative control for the P. falciparum blood stage
lysate (lane 2). Prestained molecular mass markers (SDS-7B; Sigma) are shown
on the left.
TABLE 1. In vitro inhibition of P. falciparum FID-3 merozoite
invasion by purified anti-P60 IgG
IgG Concn(mg/ml) % Parasitemia
a % Inhibition
Preimmune 2,000 4.03 6 0.03 0
Purified anti-P60 125 2.90 6 0.2 28
250 2.76 6 0.1 32
500 2.5 6 0.16 38
1,000 1.70 6 0.04 60
2,000 1.25 6 0.1 70
a Each value represents the mean (6 standard deviation) of the percent
parasitemia obtained in triplicate wells. The parasitemia at zero hour was 0.5%.
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fragments spanning more than one epitope (Fig. 1). The high-
est Ab response was seen against the peptides represented by
P18 and T1: the endpoint ELISA titers were as high as 1/10,000
for these peptides (Fig. 6). Peptide PT18 showed a reactivity
similar to that of P18 in this assay. In the case of P32 also the
response was focused on the sequences represented by PT18 or
P18 (data not shown). We also performed ELISA in which
specific Abs could bind competitively to a given peptide in
solution or to P60 coating the wells. Results of the competitive
ELISA experiments further supported the above observations,
and a dose-dependent inhibition was observed with the con-
stituent peptides, except the unrelated control peptide (Fig. 7).
Of all the constituent peptides of P60, P18 was the most ef-
fective, causing an inhibition of 77.1% at a concentration of
6.25 nmol.
To determine whether humoral response to the peptides P60
and P32 was genetically restricted, mice of different inbred
strains, namely, FVB, BALB/c, SJL, DBA/2j, and C3H/He
were primed and boosted twice with both peptides. All the
FIG. 4. Time course of P. yoelii nigeriensis infection in 15 BALB/c mice
immunized with P60 and challenged 10 days after the last boost. Parasitemia is
expressed as the percentage of infected erythrocytes. Ten immunized mice which
did not develop parasitemia and remained slide negative are not included in the
figure. F, profiles of parasitemia in two control mice which received adjuvant
only; }, course of parasitemia in five immunized mice which developed para-
sitemia; 1, death of the animal.
FIG. 5. Kinetics of peptide-specific IgG response in BALB/c mice immu-
nized with P60 as monitored by ELISA. Immunization of control mice with CFA
in PBS did not induce detectable level of peptide-specific Abs.
FIG. 6. Fine specificities of humoral responses generated in BALB/c mice
immunized with P60. The animals were primed on day 0 and boosted on day 28
with P60. Sera collected on day 35 were tested in an ELISA with different peptide
constructs as capture antigens.
FIG. 7. Inhibition of binding of anti-P60 mouse Ab to P60 in an ELISA.
Mouse serum diluted to 1/2,000 was preincubated with the indicated amounts
(final concentrations) of different peptide fragments before being added to the
ELISA plate coated with P60. VH-1 is an unrelated peptide used as a negative
control in this assay.
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immunized mice generated an Ab response to P60, although
the response varied in different haplotypes (Fig. 8). Both pep-
tides generated the highest response in H-2d mice, where Ab
endpoint titers of 1/100,000 were obtained. Immunization with
P32 showed genetic restriction of the immune response: high
levels of anti-peptide Abs were generated in BALB/c (H-2d)
and C57BL/6 (H-2b) mice, whereas it failed to induce Abs in
C3H/He (H-2k) mice (Fig. 9).
Subtyping of IgG. Since the isotype of an Ab is considered
important in determining the protective nature of the immune
response to malaria infection (5, 45), we also carried out sub-
typing of IgG response in BALB/c mice, induced upon P60
immunization. Endpoint analysis of IgG subtypes obtained
from protected and unprotected mice indicated that IgG1,
IgG2a, IgG2b, and IgG3 were generated (Fig. 10). While IgG3
could be detected at up to 1/1,000 dilution in protected mice,
the levels of IgG3 were somewhat lower (1/100) in unprotected
mice. We observed a minor difference between the levels of
IgG2b in the protected and unprotected mice: endpoint titers
of 1/8,000 and 1/2,000 were obtained for the protected and
unprotected mice, respectively. It is noteworthy that no differ-
ence between the levels of the subisotype IgG2a, which has
been implicated in altering the course of parasitemia in P. yoelii
infection, in the protected and unprotected mice were ob-
served in the present analysis (5).
Cellular immune response to peptide immunization. To de-
termine whether the T-epitope sequences incorporated in P60
induced T-helper cell functions, in vitro experiments involving
peptide-driven cell proliferation were carried out. A group of
inbred BALB/c mice (four mice) were immunized with P60,
and 12 days later, cells from the draining LN were cocultured
in vitro with the homologous peptide as well as with the con-
stituent peptides at varying concentrations. The maximum pro-
liferation in each case was observed with the immunizing pep-
tide (P60) (100 mg/ml; SI 5 28.3). In P60-immunized mice, the
proliferation of LN cells was also observed in response to (in
decreasing order) P32 (SI at 100 mg/ml, 23.4), T1 (SI at 50
mg/ml, 12.8), and PT18 (SI at 25 mg/ml, 4.0) (Fig. 11A). How-
ever, we did not observe any significant lymphocyte prolifera-
tion in response to the peptide T2 (aa 362 to 381), which has
been previously described as a T-helper epitope (17). The
results of cellular proliferation experiments with P32 are sum-
marized in Fig. 11B.
FIG. 8. Ab response to P60 as measured by ELISA in sera from different
strains of mice immunized with carrier-free P60. Sera obtained from mice im-
munized with the adjuvant alone from each of these strains did not show the
presence of Abs against P60. The ELISA titers shown are the geometric means
(6 standard deviations) of the endpoint titers obtained from eight immunized
mice.
FIG. 9. Genetic restriction profile of P32 in different strains of inbred mice.
Mice receiving CFA alone did not show detectable levels of peptide-specific Abs
in either of the strains used in this study. The titers shown are the geometric
means of the individual titers obtained from six to eight immunized mice.
FIG. 10. Profile of peptide-specific IgG subisotype responses in protected
and unprotected BALB/c mice as determined by ELISA.
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Cytokine profile. In order to determine the type of T-helper
cells involved in lymphocyte proliferation, cytokine analysis
was carried out. The supernatants were collected from lym-
phoproliferative cultures after 72 h of incubation following in
vitro peptide stimulation. Production of TH-1-derived IFN-g
and IL-2 and TH-2-derived IL-4 was estimated by using ELISA
kits at varying concentrations of P60. At the antigen concen-
tration of 25 mg/ml (the maximum SI was observed at this
concentration), the levels of IFN-g, IL-2 and IL-4 secreted
from the stimulated lymphocytes were significantly higher than
those in the unstimulated lymphocytes, indicating stimulation
of both the TH-1 and TH-2 subsets of cells (e.g., the amount of
IFN-g released on stimulation with 10 mg of P60/ml was 980
pg/ml) (Table 2).
DISCUSSION
The main aim of the present study was to design peptide
sequences containing malaria-related T epitopes which could
generate a boostable region II-specific Ab response in addition
to stimulating effector T cells. With this in view, peptides P60
and P32, both containing T-cell determinants and the region II
sequence (Fig. 1), were synthesized and characterized. We
found that immunization with the synthetic peptides produced
an amanestic Ab response in mice and that significant levels of
Abs are maintained for an extended period of time. The high-
titer anti-peptide Ab response in mice and rabbits was elicited
without conjugating the peptides to any carrier protein. We
also found that BALB/c mice immunized with these two P.
falciparum-based peptides developed partial protection against
a heterologous challenge with P. yoelii blood stage parasites. It
thus appears that both P32 and P60 contain determinants ca-
pable of producing protective immune responses in mice. We
showed earlier that anti-region II peptide Abs inhibited mer-
ozoite invasion of erythrocytes and recognized a TRAP-like
protein in the P. falciparum blood stage lysate (38). The results
of immunoassays (Western blot and IFA) with anti-P60 Abs in
the present study show that these Abs can recognize some
protein(s) of the blood stage of P. falciparum and can also
cross-react with P. yoelii blood stage parasites, and they may be
at least partially involved in protective immunity in mice. How-
ever, the protein that is recognized by the anti-P60 Abs seems
to have lower mobility than the protein identified by anti-
region II Abs earlier (38). From the Western blot assays it
appears that the protein recognized by anti-P60 Abs is different
from the well-characterized sporozoite stage P. falciparum an-
tigens CSP and TRAP (SSP-2), at least as far as mobility in
SDS-polyacrylamide gel electrophoresis is concerned. Since we
repeatedly failed to observe the faster-moving band beyond the
70-kDa mark (38), it is difficult to say from these results alone
if there is more than one blood stage protein that cross-reacts
with anti-region II peptides or if the observed difference in
protein mobility is due to experimental conditions with respect
to the parasite lysate preparation or a discrepancy in the
marker proteins. However, it may be emphasized that with
anti-peptide Abs only one major band was observed in both the
previous (38) and the present study. No further attempts to
characterize this protein were undertaken at this time.
Immune responses to the synthetic peptides were further
analyzed to investigate their fine specificities. Results of dif-
ferent immunoassays have indicated that in mice a significant
amount of the polyclonal Ab response to immunization with
P60 was focused on the region II sequence in the peptide. The
ELISA results also showed that P18 and PT18 reacted equally
well with the peptide antisera. This indicates that despite a few
differences in the amino acid sequences (Fig. 1) these two
otherwise homologous peptides share common B-cell epitopes.
We found that the P60-primed LN cells proliferated on stim-
ulation with the peptide itself and the constituent peptides P32,
T1, and P18. Stimulation with the homologous peptide PT18
also produced significant proliferation, indicating the presence
of cross-reactive T-cell determinants in P18 and PT18. Simi-
larly, the LN cells from P32-primed mice also proliferated
upon stimulation with P32 itself and its constituent peptides,
T1 and PT18 (P18), indicating that both T1 and P18 contain
T-helper determinants in their sequences. While T1 represents
FIG. 11. In vitro cellular proliferative responses with various peptides. BALB/c mice were immunized with either P60 (A) or P32 (B), and the LN cells were
stimulated with the indicated peptides. Concanavalin A (1 mg/ml) was used as a positive test antigen. Each data point represents an average of values obtained in
quadruplicate wells. The maximum background incorporations in the absence of antigen were 2,229 cpm (A) and 1,475 cpm (B).
TABLE 2. In vitro production of cytokines from LN cells from
immunized mice following stimulation with P60
Concn of P60
(mg/ml)
Level of cytokine released (pg/ml)a
IL-4 IL-2 IFN-g
0 12 68 380
10 80 200 960
25 200 240 1,700
50 240 220 2,200
100 260 320 1,260
a Supernatants obtained after 72 h of in vitro lymphoproliferative culture were
used to assay the generation of cytokines.
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a well-known T-helper epitope (18) and a cytotoxic-T-lympho-
cyte epitope within its sequence (24, 37), we were somewhat
surprised to find that the region II peptide sequences, P18 and
PT18, also contain T-helper epitopes. The fact that we also
observed a strong Ab response focused on this epitope upon
P32 and P60 immunization indicates that these peptide se-
quences contain overlapping B- and T-cell epitopes. Clearly,
P32 and P60, lying downstream of the immunodominant re-
peats, represent high-epitopic-density regions of CSP. The oc-
currence of overlapping B- and T-cell epitopes in the above-
mentioned peptides may not be surprising; in several antigenic
proteins the B- and T-cell epitopes are often located close to
each other (15, 27). On the other hand, immunization with
either P18 or PT18, which apparently contain both B- and
T-cell determinants, did not induce any detectable Ab re-
sponse in rabbits or in BALB/c mice. Keeping in mind that
short peptides containing B- and T-cell epitopes can produce
high levels of specific Ab responses, the reasons for this ob-
servation are not clear. But it has been shown that in short
peptides, T cells may not always induce an Ab response in B
cells when their determinants overlap (36). It is also suggested
that pathogens causing the dominant T-cell determinants to
overlap with the critical B-cell determinant may interfere with
Ab responses detrimental to the pathogen. This may well be
one of the several possible reasons why the B-cell determinants
in region II sequences remain largely cryptic during the course
of natural infection (3).
The fine specificities of the Ab humoral immune responses
in P. falciparum-infected individuals are generally dominated
by the repeat peptide structures, and the region II conserved
sequence seems to be a cryptic B epitope, at least during the
course of natural infection (3). One of the reasons for this may
be that the CSP repeats dominate the structural features of the
protein in such a manner that the region II sequences, which
lie downstream of the repeats, are not easily accessible to the
immune system in the intact protein. On the other hand, it has
also been reported that B cells may respond best against rigid
and highly repetitive surface antigens of pathogens and may
not even require T-helper cells for this (1). The repeats are
most likely to represent highly structured B epitopes (6), the
immune response to which could easily dominate the re-
sponses to other regions of CSP even if they are exposed.
However, these explanations will remain speculative until
structural details of malaria proteins containing repeats, such
as CSP, become available. In another study, immunization with
a repeatless CSP construct of P. falciparum in mice showed
that the region II sequences still remained poorly immuno-
genic when Ab specificity was determined by using overlapping
octapeptides (44).
Whatever the reason may be, it is quite clear that region II
is not as immunodominant as some other malaria epitopes, and
it is likely that the immune response to such cryptic epitopes is
raised only very slowly. It is well known that natural immunity
to malaria in individuals living in areas where it is endemic is
not fully acquired before adolescence, even following repeated
infections (11, 12). Masking of the crucial protective epitopes
in an antigen during the course of natural infection has also
been reported in the case of tryptomastigote surface antigen 1
(TSA-1) of Trypanosoma cruzi (46). When mice were immu-
nized with the intact recombinant protein, the Ab response was
found to be mainly focused on the carboxy-terminal region of
the protein, which did not provide any protection against a
challenge infection. On the other hand, immunization with a
recombinant N-terminal fragment provided protection, leading
to the conclusion that in TSA-1, the protective epitopes of the
N-terminal region remain cryptic in the intact protein and that
the removal of the immunodominant carboxy-terminal region
from the protein allows the immune response to be focused on
these cryptic, but crucial, epitopes (46). The results of the
present study also suggest that through the use of synthetic
peptides it may be possible to focus Ab response on the
epitopes which tend to remain cryptic during immunization
with the intact protein. But it should also be emphasized that
it may not always be possible to predict the nature of immune
responses from multiepitopic peptides. We and others have
shown that such immunogens may be polar, and there are no
rules yet to design these molecules for specific immune re-
sponses (10, 16, 39).
In general, immune response to short synthetic peptides is
genetically restricted. Inclusion of appropriate T-cell determi-
nants may help to overcome this problem. In fact, in the case
of the shorter peptide, P32, the immune response was re-
stricted to H-2d and H-2b haplotypes of mice. On the other
hand, immunization with P60, which contains several T-cell
determinants, produced significant response in all the haplo-
types tested. These results suggest that in a synthetic peptide
immunogen, inclusion of more than one T epitope may at
times be a reasonable way to circumvent the problem of ge-
netic restriction of the immune response. In a multiple-antigen
peptide vaccine construct designed to produce high levels of
Abs against P. yoelii CSP repeats, two T-helper epitopes were
used (43).
Differential activation of T-cell subsets, TH-1 and TH-2,
seems to play a crucial role in parasitic diseases (26, 30, 31). In
malaria also, TH subsets have been implicated in modulating
the course of infection during different stages of the parasite
life cycle (31). The results of our cytokine analyses of the
supernatants obtained from in vitro cellular proliferation ex-
periments with P60 indicated that both the TH-1 and TH-2
subsets of T cells were activated upon peptide immunization.
Since mature erythrocytes do not bear or express major histo-
compatibility complex class I or II antigens, it is difficult to
envisage a direct role for T cells in protective immunity against
blood stages of the parasite. But at the same time, activated
lymphocytes release a battery of cytokines, which could medi-
ate the functions of phagocytic cells and possibly promote
phagocytosis of the intraerythrocytic parasite. For example,
IFN-g, which is known to play an important role in modulating
infection (40), is released by both TH-1 and CD81 cells. Spe-
cific activation of T cells could have a role in inducing protec-
tive immunity against malaria (29, 31).
The relative roles of different immunoglobulin subtypes
have also been assessed, and there is evidence that in both
human and rodent malaria, the distribution of Ab subisotypes
can modulate the course of infection (5, 45). We found notice-
ably higher levels of IgG3 and IgG2b in protected mice com-
pared to those in unprotected mice. However, no differences
were seen between the levels of IgG2a in protected and un-
protected mice. In an earlier study, the IgG2a subisotype alone
was found to alter the course of parasitemia in mice infected
with P. yoelii (45). The qualitative and quantitative roles of Abs
in malaria are not well understood and need to be evaluated
for the development of malaria vaccine (4).
Can a functional conserved malaria protein sequence which
is also a part of self molecules like thrombospondin and pro-
perdin be considered for inclusion in a peptide malaria vaccine
construct? It can be validly argued that the induction of an
immune response to the conserved motif could give rise to
autoimmune responses, as shown for the heat shock protein 70
(hsp-70) cognate parasite protein. At the same time, several P.
falciparum proteins, viz., Pf25, PfMSP-1, and PfP41, contain
sequences homologous to those of host proteins, such as epi-
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dermal growth factor (23), the intermediate filament protein,
and the human aldolase enzyme, respectively (8); and, signif-
icantly, none of these sequences have been shown to induce or
be a target of any autoimmune response. In conclusion, the
present study indicates that (i) through appropriate synthetic
peptides it may be possible to focus immune response on the
epitopes that remain cryptic when the whole antigen is pre-
sented to the immune system, (ii) that linear, nonpolymeric
peptide can be a potent immunogen, (iii) that inclusion of
more than one T epitope may be necessary to circumvent the
problem of genetic restriction in peptide immunization, and
(iv) that highly conserved motifs in malaria surface antigens
may be useful targets for inclusion in synthetic peptide malaria
vaccine constructs.
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